NEW YORK (Thomson Financial) - Hollis-Eden Pharmaceuticals Inc. Monday said
a preclinical study of cancer drug candidate Apoptone showed the compound
inhibited the growth of androgen-independent human tumors LuCaP 35V grown
subcutaneously as well as growth of C4-2B cells in the bone environment of
castrated mice.
The company also said it has received regulatory clearance to start a Phase
I/II dose ranging clinical trial with Apoptone in prostate cancer patients. The
patient population for the study will be considered "late stage," defined as
having failed at least one round of chemotherapy.
Hollis-Eden shares closed at $1.53 on Wednesday.
Christie Rizk
cr/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|